Skip to main content
SpringerLink
Log in

Impairments in Motor Neurons, Interneurons and Astrocytes Contribute to Hyperexcitability in ALS: Underlying Mechanisms and Paths to Therapy

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterised by the loss of motor neurons leading to progressive paralysis and death. Using transcranial magnetic stimulation (TMS) and nerve excitability tests, several clinical studies have identified that cortical and peripheral hyperexcitability are among the earliest pathologies observed in ALS patients. The changes in the electrophysiological properties of motor neurons have been identified in both sporadic and familial ALS patients, despite the diverse etiology of the disease. The mechanisms behind the change in neuronal signalling are not well understood, though current findings implicate intrinsic changes in motor neurons and dysfunction of cells critical in regulating motor neuronal excitability, such as astrocytes and interneurons. Alterations in ion channel expression and/or function in motor neurons has been associated with changes in cortical and peripheral nerve excitability. In addition to these intrinsic changes in motor neurons, inhibitory signalling through GABAergic interneurons is also impaired in ALS, likely contributing to increased neuronal excitability. Astrocytes have also recently been implicated in increasing neuronal excitability in ALS by failing to adequately regulate glutamate levels and extracellular K+ concentration at the synaptic cleft. As hyperexcitability is a common and early feature of ALS, it offers a therapeutic and diagnostic target. Thus, understanding the underlying pathways and mechanisms leading to hyperexcitability in ALS offers crucial insight for future development of ALS treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cleveland DW, Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2:806–819. doi:10.1038/35097565

    Article  CAS  PubMed  Google Scholar 

  2. Kiernan JA, Hudson AJ (1991) Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain 114(Pt 2):843–853

    Article  PubMed  Google Scholar 

  3. Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, Millul A, Benn E et al (2010) Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 81:385–390. doi:10.1136/jnnp.2009.183525

    Article  PubMed  Google Scholar 

  4. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. Lancet 377:942–955. doi:10.1016/S0140-6736(10)61156-7

    Article  CAS  PubMed  Google Scholar 

  5. Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330:585–591. doi:10.1056/NEJM199403033300901

    Article  CAS  PubMed  Google Scholar 

  6. Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews

  7. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293–299

    Article  CAS  PubMed  Google Scholar 

  8. Chiò A (1999) ISIS survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 246(Suppl 3):III1–III5

    Article  PubMed  Google Scholar 

  9. Bowser R, Turner MR, Shefner J (2011) Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol 7:631–638. doi:10.1038/nrneurol.2011.151

    Article  CAS  PubMed  Google Scholar 

  10. Chen S, Sayana P, Zhang X, Le W (2013) Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener 8:28. doi:10.1186/1750-1326-8-28

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ling S-C, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79:416–438. doi:10.1016/j.neuron.2013.07.033

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Renton AE, Chiò A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17:17–23. doi:10.1038/nn.3584

    Article  CAS  PubMed  Google Scholar 

  13. Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci 14:248–264. doi:10.1038/nrn3430

    Article  CAS  PubMed  Google Scholar 

  14. Bae JS, Simon NG, Menon P, Vucic S, Kiernan MC (2013) The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol 9:65–74. doi:10.3988/jcn.2013.9.2.65

    Article  PubMed  PubMed Central  Google Scholar 

  15. Vucic S, Nicholson GA, Kiernan MC (2008) Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 131:1540–1550. doi:10.1093/brain/awn071

    Article  PubMed  Google Scholar 

  16. Blair IP, Williams KL, Warraich ST, Durnall JC, Thoeng AD, Manavis J, Blumbergs PC, Vucic S et al (2010) FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry 81:639–645. doi:10.1136/jnnp.2009.194399

    Article  PubMed  Google Scholar 

  17. Williams KL, Fifita JA, Vucic S, Durnall JC, Kiernan MC, Blair IP, Nicholson GA (2013) Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry 84:931–935. doi:10.1136/jnnp-2012-304529

    Article  PubMed  Google Scholar 

  18. Mills KR, Nithi KA (1997) Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Muscle Nerve 20:1137–1141. doi:10.1002/(SICI)1097-4598(199709)20:9<1137::AID-MUS7>3.0.CO;2-9

    Article  CAS  PubMed  Google Scholar 

  19. de Carvalho M, Swash M (2013) Fasciculation potentials and earliest changes in motor unit physiology in ALS. J Neurol Neurosurg Psychiatry 84:963–968. doi:10.1136/jnnp-2012-304545

    Article  PubMed  Google Scholar 

  20. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, Mills K, Mitsumoto H et al (2008) Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 119:497–503. doi:10.1016/j.clinph.2007.09.143

    Article  PubMed  Google Scholar 

  21. Vucic S, Kiernan MC (2006) Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 129:2436–2446. doi:10.1093/brain/awl172

    Article  PubMed  Google Scholar 

  22. Menon P, Kiernan MC, Vucic S (2015) Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin Neurophysiol 126:803–809. doi:10.1016/j.clinph.2014.04.023

    Article  PubMed  Google Scholar 

  23. Weber M, Eisen A, Stewart H, Hirota N (2000) The split hand in ALS has a cortical basis. J Neurol Sci 180:66–70. doi:10.1016/S0022-510X(00)00430-5

    Article  CAS  PubMed  Google Scholar 

  24. Kujirai T, Caramia MD, Rothwell JC, Day BL, Thompson PD, Ferbert A, Wroe S, Asselman P et al (1993) Corticocortical inhibition in human motor cortex. J Physiol Lond 471:501–519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. McClintock SM, Freitas C, Oberman L, Lisanby SH, Pascual-Leone A (2011) Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia. Biol Psychiatry 70:19–27. doi:10.1016/j.biopsych.2011.02.031

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ziemann U, Winter M, Reimers CD, Reimers K, Tergau F, Paulus W (1997) Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis evidence from paired transcranial magnetic stimulation. Neurology 49:1292–1298. doi:10.1212/WNL.49.5.1292

    Article  CAS  PubMed  Google Scholar 

  27. Vucic S, Kiernan MC (2006) Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol 117:1458–1466. doi:10.1016/j.clinph.2006.04.016

    Article  PubMed  Google Scholar 

  28. Bostock H, Rothwell JC (1997) Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol 498:277–294

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bostock H, Cikurel K, Burke D (1998) Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 21:137–158. doi:10.1002/(SICI)1097-4598(199802)21:2<137::AID-MUS1>3.0.CO;2-C

    Article  CAS  PubMed  Google Scholar 

  30. Bostock H, Sharief MK, Reid G, Murray NMF (1995) Axonal ion channel dysfunction in amyotrophic lateral sclerosis. Brain 118:217–225. doi:10.1093/brain/118.1.217

    Article  PubMed  Google Scholar 

  31. Pieri M, Carunchio I, Curcio L, Mercuri NB, Zona C (2009) Increased persistent sodium current determines cortical hyperexcitability in a genetic model of amyotrophic lateral sclerosis. Exp Neurol 215:368–379. doi:10.1016/j.expneurol.2008.11.002

    Article  CAS  PubMed  Google Scholar 

  32. Mogyoros I, Kiernan MC, Burke D, Bostock H (1998) Strength-duration properties of sensory and motor axons in amyotrophic lateral sclerosis. Brain 121:851–859. doi:10.1093/brain/121.5.851

    Article  PubMed  Google Scholar 

  33. Kanai K, Kuwabara S, Misawa S, Tamura N, Ogawara K, Nakata M, Sawai S, Hattori T et al (2006) Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain 129:953–962. doi:10.1093/brain/awl024

    Article  PubMed  Google Scholar 

  34. Wagle-Shukla A, Ni Z, Gunraj CA, Bahl N, Chen R (2009) Effects of short interval intracortical inhibition and intracortical facilitation on short interval intracortical facilitation in human primary motor cortex. J Physiol 587:5665–5678. doi:10.1113/jphysiol.2009.181446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Moser JM, Bigini P, Schmitt-John T (2013) The wobbler mouse, an ALS animal model. Mol Gen Genomics 288:207–229. doi:10.1007/s00438-013-0741-0

    Article  CAS  Google Scholar 

  36. McGown A, McDearmid JR, Panagiotaki N, Tong H, Al Mashhadi S, Redhead N, Lyon AN, Beattie CE et al (2013) Early interneuron dysfunction in ALS: insights from a mutant sod1 zebrafish model. Ann Neurol 73:246–258. doi:10.1002/ana.23780

    Article  CAS  PubMed  Google Scholar 

  37. Zhang W, Zhang L, Liang B, Schroeder D, Zhang Z, Cox GA, Li Y, Lin D-T (2016) Hyperactive somatostatin interneurons contribute to excitotoxicity in neurodegenerative disorders. Nat Neurosci 19:557–559. doi:10.1038/nn.4257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Nieto-Gonzalez JL, Moser J, Lauritzen M, Schmitt-John T, Jensen K (2011) Reduced GABAergic inhibition explains cortical hyperexcitability in the wobbler mouse model of ALS. Cereb Cortex 21:625–635. doi:10.1093/cercor/bhq134

    Article  PubMed  Google Scholar 

  39. Nihei K, McKee AC, Kowall NW (1993) Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol 86:55–64

    Article  CAS  PubMed  Google Scholar 

  40. Petri S, Krampfl K, Hashemi F, Grothe C, Hori A, Dengler R, Bufler J (2003) Distribution of GABAA receptor mRNA in the motor cortex of ALS patients. J Neuropathol Exp Neurol 62:1041–1051. doi:10.1093/jnen/62.10.1041

    Article  CAS  PubMed  Google Scholar 

  41. Lloyd CM, Richardson MP, Brooks DJ, Al-Chalabi A, Leigh PN (2000) Extramotor involvement in ALS: PET studies with the GABAA ligand [11C]flumazenil. Brain 123:2289–2296. doi:10.1093/brain/123.11.2289

    Article  PubMed  Google Scholar 

  42. Vucic S, Kiernan MC (2010) Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry 81:222–227. doi:10.1136/jnnp.2009.183079

    Article  PubMed  Google Scholar 

  43. Kuo JJ, Siddique T, Fu R, Heckman CJ (2005) Increased persistent Na+ current and its effect on excitability in motoneurones cultured from mutant SOD1 mice. J Physiol 563:843–854. doi:10.1113/jphysiol.2004.074138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Geevasinga N, Menon P, Ng K, Bos MVD, Byth K, Kiernan MC, Vucic S (2016) Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 0:1–9. doi:10.1080/21678421.2016.1188961

    Google Scholar 

  45. Vucic S, Lin CS-Y, Cheah BC, Murray J, Menon P, Krishnan AV, Kiernan MC (2013) Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain 136:1361–1370. doi:10.1093/brain/awt085

    Article  PubMed  Google Scholar 

  46. Jiang Y-M, Yamamoto M, Kobayashi Y, Yoshihara T, Liang Y, Terao S, Takeuchi H, Ishigaki S et al (2005) Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol 57:236–251. doi:10.1002/ana.20379

    Article  CAS  PubMed  Google Scholar 

  47. Shibuya K, Misawa S, Arai K, Nakata M, Kanai K, Yoshiyama Y, Ito K, Isose S et al (2011) Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: an immunohistochemical study. Exp Neurol 232:149–153. doi:10.1016/j.expneurol.2011.08.015

    Article  CAS  PubMed  Google Scholar 

  48. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W (2006) The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta (BBA) - Mol Basis Dis 1762:1068–1082. doi:10.1016/j.bbadis.2006.05.002

    Article  CAS  Google Scholar 

  49. Rothstein J (1994) Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 68:7–20–7

    Google Scholar 

  50. Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47:S233–S241

    Article  CAS  PubMed  Google Scholar 

  51. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, Pestronk A, Stauch BL et al (1990) Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28:18–25. doi:10.1002/ana.410280106

    Article  CAS  PubMed  Google Scholar 

  52. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW (1995) Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38:73–84

    Article  CAS  PubMed  Google Scholar 

  53. Pardo AC, Wong V, Benson LM, Dykes M, Tanaka K, Rothstein JD, Maragakis NJ (2006) Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1G93A mice. Exp Neurol 201:120–130. doi:10.1016/j.expneurol.2006.03.028

    Article  CAS  PubMed  Google Scholar 

  54. Lin C-LG, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, Rothstein JD (1998) Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20:589–602. doi:10.1016/S0896-6273(00)80997-6

    Article  CAS  PubMed  Google Scholar 

  55. Nagai M, Abe K, Okamoto K, Itoyama Y (1998) Identification of alternative splicing forms of GLT-1 mRNA in the spinal cord of amyotrophic lateral sclerosis patients. Neurosci Lett 244:165–168. doi:10.1016/S0304-3940(98)00158-X

    Article  CAS  PubMed  Google Scholar 

  56. Kofuji P, Newman E (2004) Potassium buffering in the central nervous system. Neuroscience 129:1045–1056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Haj-Yasein NN, Jensen V, Vindedal GF, Gundersen GA, Klungland A, Ottersen OP, Hvalby O, Nagelhus EA (2011) Evidence that compromised K+ spatial buffering contributes to the epileptogenic effect of mutations in the human Kir4.1 gene (KCNJ10). Glia 59:1635–1642. doi:10.1002/glia.21205

    Article  PubMed  Google Scholar 

  58. Djukic B, Casper KB, Philpot BD, Chin L-S, McCarthy KD (2007) Conditional knock-out of Kir4.1 leads to glial membrane depolarization, inhibition of potassium and glutamate uptake, and enhanced short-term synaptic potentiation. J Neurosci 27:11354–11365. doi:10.1523/JNEUROSCI.0723-07.2007

    Article  CAS  PubMed  Google Scholar 

  59. Bataveljić D, Nikolić L, Milosević M, Todorović N, Andjus PR (2012) Changes in the astrocytic aquaporin-4 and inwardly rectifying potassium channel expression in the brain of the amyotrophic lateral sclerosis SOD1G93A rat model. Glia 60:1991–2003. doi:10.1002/glia.22414

    Article  PubMed  Google Scholar 

  60. Kaiser M, Maletzki I, Hülsmann S, Holtmann B, Schulz-Schaeffer W, Kirchhoff F, Bähr M, Neusch C (2006) Progressive loss of a glial potassium channel (KCNJ10) in the spinal cord of the SOD1 (G93A) transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 99:900–912. doi:10.1111/j.1471-4159.2006.04131.x

    Article  CAS  PubMed  Google Scholar 

  61. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10:615–622. doi:10.1038/nn1876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, Song S, Likhite S et al (2011) Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29:824–828. doi:10.1038/nbt.1957

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Philips T, Robberecht W (2011) Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. The Lancet Neurology 10:253–263. doi:10.1016/S1474-4422(11)70015-1

    Article  CAS  PubMed  Google Scholar 

  64. Das MM, Svendsen CN (2015) Astrocytes show reduced support of motor neurons with aging that is accelerated in a rodent model of ALS. Neurobiol Aging 36:1130–1139. doi:10.1016/j.neurobiolaging.2014.09.020

    Article  CAS  PubMed  Google Scholar 

  65. Almad AA, Doreswamy A, Gross SK, Richard J-P, Huo Y, Haughey N, Maragakis NJ (2016) Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. Glia 64:1154–1169. doi:10.1002/glia.22989

    Article  PubMed  PubMed Central  Google Scholar 

  66. Leroy F, Zytnicki D (2015) Is hyperexcitability really guilty in amyotrophic lateral sclerosis? Neural Regen Res 10:1413–1415. doi:10.4103/1673-5374.165308

    Article  PubMed  PubMed Central  Google Scholar 

  67. Leroy F, d’Incamps BL, Imhoff-Manuel RD, Zytnicki D (2014) Early intrinsic hyperexcitability does not contribute to motoneuron degeneration in amyotrophic lateral sclerosis. eLife 3:e04046. doi:10.7554/eLife.04046

    Article  PubMed  PubMed Central  Google Scholar 

  68. Delestrée N, Manuel M, Iglesias C, Elbasiouny SM, Heckman CJ, Zytnicki D (2014) Adult spinal motoneurones are not hyperexcitable in a mouse model of inherited amyotrophic lateral sclerosis. J Physiol 592:1687–1703. doi:10.1113/jphysiol.2013.265843

    Article  PubMed  PubMed Central  Google Scholar 

  69. Shibuya K, Misawa S, Kimura H, Noto Y-I, Sato Y, Sekiguchi Y, Iwai Y, Mitsuma S et al (2015) A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: efficacy and safety of sodium channel blocker phase II trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 16:353–358. doi:10.3109/21678421.2015.1038277

    Article  CAS  PubMed  Google Scholar 

  70. Weiss MD, Macklin EA, Simmons Z et al (2016) A randomized trial of mexiletine in ALS safety and effects on muscle cramps and progression. Neurology 86:1474–1481. doi:10.1212/WNL.0000000000002507

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SSW, Sandoe J, Perez NP, Williams LA et al (2014) Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep 7:1–11. doi:10.1016/j.celrep.2014.03.019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Engel M, Do-Ha D, Muñoz SS, Ooi L (2016) Common pitfalls of stem cell differentiation: a guide to improving protocols for neurodegenerative disease models and research. Cell Mol Life Sci 73:3693–3709. doi:10.1007/s00018-016-2265-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Devlin A-C, Burr K, Borooah S, Foster JD, Cleary EM, Geti I, Vallier L, Shaw CE et al (2015) Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun 6:5999. doi:10.1038/ncomms6999

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Illawarra Health and Medical Research Institute, School of Biological Sciences, University of Wollongong, Wollongong, NSW, 2522, Australia

    Dzung Do-Ha & Lezanne Ooi

  2. School of Medicine, Western Sydney University, Penrith, NSW, Australia

    Yossi Buskila

  3. The MARCS Institute, Western Sydney University, Penrith, NSW, Australia

    Yossi Buskila

Authors
  1. Dzung Do-Ha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yossi Buskila
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lezanne Ooi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lezanne Ooi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Do-Ha, D., Buskila, Y. & Ooi, L. Impairments in Motor Neurons, Interneurons and Astrocytes Contribute to Hyperexcitability in ALS: Underlying Mechanisms and Paths to Therapy. Mol Neurobiol 55, 1410–1418 (2018). https://doi.org/10.1007/s12035-017-0392-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-017-0392-y

Keywords

Search

Navigation